Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Daptomycin.

Caroline Fenton1, Gillian M Keating, Monique P Curran

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|February 19, 2004
PubMed
Summary
This summary is machine-generated.

Daptomycin, an antibacterial, effectively treats complicated skin infections caused by Gram-positive bacteria. Clinical trials show it is as effective as standard therapies with a similar safety profile.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clozapine is the approved option in treatment-resistant schizophrenia and requires careful management.

Drugs & therapy perspectives : for rational drug selection and use·2023
Same author

Antidepressants with anti-inflammatory properties may be useful in long COVID depression.

Drugs & therapy perspectives : for rational drug selection and use·2022
Same author

mRNA COVID-19 vaccines are well tolerated and myopericarditis is a rare adverse event following immunisation.

Drugs & therapy perspectives : for rational drug selection and use·2022
Same author

Emerging small molecule antivirals may fit neatly into COVID-19 treatment.

Drugs & therapy perspectives : for rational drug selection and use·2022
Same author

COVID-19: State of the Vaccination.

Drugs & therapy perspectives : for rational drug selection and use·2021
Same author

Correction to: Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2019
Same journal

Ecnoglutide: First Approvals.

Drugs·2026
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Clinical Trials

Background:

  • Daptomycin is a lipopeptide antibiotic with rapid in vitro activity against Gram-positive cocci.
  • It is approved for complicated skin and skin structure infections (cSSSIs).

Purpose of the Study:

  • To evaluate the efficacy and safety of intravenous daptomycin compared to standard therapy in patients with cSSSIs.

Main Methods:

  • Two randomized, investigator-blinded, multicenter trials were conducted.
  • Patients received intravenous daptomycin 4 mg/kg once daily or standard therapy (penicillin or vancomycin).
  • Clinical success rates and adverse events were assessed.

Main Results:

  • Daptomycin demonstrated equivalent efficacy to standard therapy, with pooled clinical success rates of 82.1% versus 82.9%.

Related Experiment Videos

  • Adverse event profiles were similar between daptomycin and vancomycin.
  • Increased creatine phosphokinase (CPK) levels occurred in 2.8% of daptomycin recipients, with only one case of muscle symptoms.

    • Conclusions:

    • Intravenous daptomycin is a viable and effective treatment option for cSSSIs caused by susceptible Gram-positive bacteria.
    • Daptomycin exhibits a comparable safety profile to standard therapies, with minimal risk of CPK elevation and muscle symptoms.